Skip to main content
SpringerLink
Log in

Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era

  • Editorial
  • Published:
Targeted Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  PubMed  CAS  Google Scholar 

  2. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664

    Article  PubMed  Google Scholar 

  3. Van Cutsem E, Nowacki M, Lang I, Cascinu S et al (2007) Randomized phase III trial of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer: the CRYSTAL trial. http://www.asco.org; ASCO Annual Meeting 2007: abstract 4000

  4. Van Cutsem E, Lang I, D’Haens G et al (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with or without cetuximab: the CRYSTAL experience. http://www.asco.org; ASCO Annual Meeting 2008: abstract 2

  5. Bockemeyer C, Bondarenko I, Hartmann J et al (2008) KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or wihtout cetuximab: the OPUS experience. http://www.asco.org; ASCO Annual Meeting 2008: abstract 4000

  6. Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286

    Article  PubMed  CAS  Google Scholar 

  7. Sartore-Bianchi A, Moroni M, Veronese S et al (2005) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238–3245

    Article  Google Scholar 

  8. Cappuzzo F, Finocchiaro G, Rossi E et al (2007) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractorycolorectal cancer patients. Ann Oncol 19:717–723

    Article  PubMed  Google Scholar 

  9. Personeni N, Fieuws S, Piessevaux H et al (2008) Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res 14(18):5869–5876

    Article  PubMed  CAS  Google Scholar 

  10. Jonker D, O’Callaghan C, Karapetis C et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048

    Article  PubMed  CAS  Google Scholar 

  11. Amado R, Wolf M, Peeters M, Van Cutsem E et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1582–1584

    Article  Google Scholar 

  12. Khambata-Ford S, Garrett C, Meropol N et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230–3237

    Article  PubMed  CAS  Google Scholar 

  13. Lievre A, Bachet J, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995

    Article  PubMed  CAS  Google Scholar 

  14. De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19(3):508–515

    Article  PubMed  Google Scholar 

  15. Lièvre A, Bachet J, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379

    Article  PubMed  Google Scholar 

  16. Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 96:1166–1169

    Article  PubMed  Google Scholar 

  17. Di Fiore F, Van Cutsem E, Laurent-Puig P et al (2008) Role of KRAS mutations in predicting response and survival in irinotecan-refractory patients treated with cetuximab and irinotecan for metastatic colorectal cancer: analysis of 281 patients with individual data. Ann Oncol 19(Suppl 6): abstract O-016

  18. Karapetis C, Khambata-Ford S, Jonker D et al (2008) KRAS Mutation status is a predictive biomarker for cetuximab benefitg in the treatment of advanced colorectal cancer—results from NIC CTG CO-17: a phase III trial of cetuximab versus best supportive care. Ann Oncol 19(Suppl 8): Late-breaking abstract 6

  19. Van Cutsem E, Lang I, D’Haens G et al (2008) KRAS status and efficacy in the Crystal study: 1st line treatment for patients with metastatic colorectal cancer receiving folfiri with or without cetuximab. Ann Oncol 19(Suppl 8): Update to abstract 710

  20. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648

    Article  PubMed  CAS  Google Scholar 

  21. Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139–1145

    Article  PubMed  CAS  Google Scholar 

  22. Loupakis F, Pollina L, Stasi I et al (2008) Evaluation of PTEN expression in colorectal cancer metastases and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. http://www.asco.org; ASCO Annual Meeting 2008: abstract 4003

  23. Tejpar S, De Roock W, Beismans B et al (2008) Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. http://www.asco.org; GI Cancers Symposium, Orlando 2008: abstract 411

Download references

Author information

Authors and Affiliations

  1. Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium

    Eric Van Cutsem & Sabine Tejpar

Authors
  1. Eric Van Cutsem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabine Tejpar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Van Cutsem.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Cutsem, E., Tejpar, S. Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era. Targ Oncol 3, 223–225 (2008). https://doi.org/10.1007/s11523-008-0097-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-008-0097-2

Keywords

Search

Navigation